Drug Profile

Levodopa - SNLD

Alternative Names: TR-012001

Latest Information Update: 29 Aug 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator SNLD
Class Antiasthmatics; Antiparkinsonians; Catecholamines; Small molecules
Mechanism of Action Dopamine receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Parkinson's disease

Most Recent Events

05 Apr 2025 Adverse events, pharmacokinetics and efficacy data from a phase II trial in Parkinson's disease presented at 77th Annual Meeting of the American Academy of Neurology 2025 (AAN-2025)
30 May 2024 SNLD completes a phase-II trial in Parkinson's disease in Japan (Intranasal) (NCT06212089)
09 Feb 2024 SNLD completes a phase I trial in Parkinson's disease in Japan (Intranasal), prior to February 2024 (jRCT2031210658)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com